US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis: Review of Adverse Effect Profiles

Author： Steven L. Galetta Clyde Markowitz

ISSN： 1172-7047

Source： CNS Drugs, Vol.19, Iss.3, 2005-01, pp. : 239-252

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Disease-Modifying Treatments for Multiple Sclerosis: The Story So Far

By Kieseier Bernd C.

CNS Drugs, Vol. 21, Iss. 6, 2007-01 ,pp. : 483-502

Adis International

Access to resources Recommend Favorite

Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 8, Iss. 6, 2009-12 ,pp. : 512-519

Bentham Science Publishers

Access to resources Recommend Favorite

Disease Modifying Treatments for Multiple Sclerosis: What is on the Horizon?

By Weilbach F.X. Gold R.

CNS Drugs, Vol. 11, Iss. 2, 1999-02 ,pp. : 133-157

Adis International

Access to resources Recommend Favorite

Pharmacogenomic characterization of US FDA-approved cytotoxic drugs

By Peters Eric J Motsinger-Reif Alison Havener Tammy M Everitt Lorraine Hardison Nicholas E Watson Venita G Wagner Michael Richards Kristy L Province Mike A McLeod Howard L

Pharmacogenomics, Vol. 12, Iss. 10, 2011-10 ,pp. : 1407-1415

Future Medicine

Access to resources Recommend Favorite

Disease-Modifying Agents for Multiple Sclerosis: Recent Advances and Future Prospects

By Menge Til

Drugs, Vol. 68, Iss. 17, 2008-01 ,pp. : 2445-2468

Adis International

Access to resources Recommend Favorite